Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERx inhaled human insulin versus subcutaneous insulin aspart in diabetes patients with COPD
2006-004731-29Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Apr 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetes mellitus type 1 (T1D) comparing Inhaled human insulin via AERx iDMS with Subcutaneous insulin aspart (2 arms). Primary endpoint: Change in pulmonary function tests from baseline to 52 weeks. Started Apr 2008; status: terminated.
02
Drugs
human insulininsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2006-004731-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004731-29.